Institut Bergonié

May 23, 2024 | link.springer.com | Maria Luisa |Institut Bergonié

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02934-7, published online 6 May 2024In the version of the article initially published, patient numbers and ratios of the trial cohorts were missing from the abstract and have now been added in the HTML and PDF versions of the article.

May 5, 2024 | link.springer.com | Maria Luisa |Institut Bergonié

AbstractFibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations).

Apr 17, 2024 | academic.oup.com | Institut Bergonié |Bart Van Vooren |Bouvy JC

Precision oncology (PO) uses molecular, phenotypic, and health data from cancer patients to target treatment and improve health outcomes.1 Genomic and molecular alterations are increasingly important in cancer diagnosis, and scientific advances are opening new treatment avenues.

Mar 22, 2024 | molecular-cancer.biomedcentral.com | Gustave Roussy |Université Paris Saclay |Le Kremlin-Bicêtre |Institut Bergonié

In this international, multi-center single-arm phase 2 trial, we enrolled different cohorts of patients including advanced CRC, renal cell carcinoma, non-small cell lung cancer (NSCLC) and sarcomas who had at least 1) one lesion eligible for SBRT and 2) one unirradiated lesion, both measurable by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).

Jan 4, 2024 | aacrjournals.org | Institut Bergonié |Gustave Roussy

Citation Alban Bessede, Florent Peyraud, Benjamin Besse, Sophie Cousin, Mathilde Cabart, François Chomy, Christophe Rey, Oren Lara, Ophélie Odin, Imane Nafia, Lucile Vanhersecke, Fabrice Barlesi, Jean-Philippe Guégan, Antoine Italiano; TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer. Clin Cancer Res 2024; https://doi.org/10.1158/1078-0432.CCR-23-2566 Download citation file: